09-09-2021, 08:29 PM
(09-09-2021, 07:07 PM)JoeKW Wrote: The FDA asked Pfizer to increase their trial size because they're concerned about the occurrences of myocarditis in young men and teenage boys. The likely delays approval/EUA until early winter which basically means early 2022 unfortunately.
If the concern was specifically myocarditis, then this shouldn't actually delay the study much, those reactions happen quite soon after vaccination, so the same long term duration would not be needed to evaluate that risk, I would think.